Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis

  title={Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis},
  author={Sheila Annie Peters},
  journal={Clinical Pharmacokinetics},
  • S. Peters
  • Published 2008
  • Biology, Chemistry
  • Clinical Pharmacokinetics
AbstractBackground and objective: The mechanistic framework of physiologically based pharmacokinetic (PBPK) models makes them uniquely suited to hypothesis testing and lineshape analysis, which help provide valuable insights into mechanisms that contribute to the observed concentration-time profiles. The aim of this article is to evaluate the utility of PBPK models for simulating oral lineshapes by optimizing clearance and distribution parameters through fitting observed intravenous… 

Physiologically Based Pharmacokinetic Modeling: A Tool for Understanding ADMET Properties and Extrapolating to Human

This work has shown that factors influencing the absorption, distribution, metabolism, and elimi‐ nation of a compound can be incorporated into a PBPK model in a mechanistic, meaningful way, if a mechanism is understood and sufficient data are available.

Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles

  • S. Peters
  • Biology, Medicine
    Clinical pharmacokinetics
  • 2008
A successful application of PBPK simulations is demonstrated to identify and quantify intestinal loss of two model compounds in rats and humans and demonstrated that the large interspecies differences associated with gut wall metabolism and gastric emptying, evident for the compounds studied, make animal model extrapolations to humans unreliable.

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

The utility of PBPK methodology for the prediction of human pharmacokinetics can be applied at different stages to enhance the understanding of the compounds in a particular chemical series, guide experiments, aid candidate selection and inform clinical trial design.

Pharmacokinetic Modelling to Study the Biodistribution of Nanoparticles

This chapter summarises the approach of PBPK models, its challenges and possibilities to assess the key ADME mechanisms involved during various mucosal routes of administration using several allometric, anthropometric and rate equations to inform drug pharmacokinetics in humans.

Physiologically based pharmacokinetics (PBPK)

The biological and mechanistic bases of PBPK models allow the extrapolation of the kinetic behavior of drugs with regard to dose, route, and species and represents a framework for mechanistic pharmacokinetic-pharmacodynamic models.

Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

This work has shown how PBPK techniques can be utilised for human PK and dose prediction and has shown the potential to increase efficiency, reduce the need for animal studies, replace clinical trials and increase PK understanding.

Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.

Physiologically‐Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues

Predicted unbound sertraline concentrations at steady‐state in human tissues did not reach concentrations determined in vitro, indicating therapeutic doses of sertRALine are unlikely to produce concentrations required for anticancer and antimicrobial activities in humans.

Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery

The generic GastroPlus ACAT model provided reasonable predictions especially for BCS class 1 compounds and for compounds of other classes, the model may be refined by obtaining more information on solubility and permeability in secondary assays.

Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective

This review has analyzed the most recent applications of PBPK models for ARVs and highlighted some of the most interesting areas of use, such as drug–drug interaction, pharmacogenetics, factors regulating absorption and tissue penetration, as well as therapy optimization in special populations.




It is concluded that the generic PBPK model is potentially a powerful and cost-effective tool for predicting the mammalian pharmacokinetics of a wide range of organic compounds, from readily available in vitro inputs only.

Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery

A generic disposition model based on tissue‐composition‐based distribution and directly scaled hepatic clearance is presented, which can be used in drug discovery to identify the critical PK issues of compound classes and to rationally guide the optimization path of the compounds toward a viable development candidate.

Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.

  • M. GermaniP. Crivori I. Poggesi
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2007

Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125

The PBPK model provides a promising tool to quantitatively link preclinical and clinical data and agrees well with the experimental measurements in dog and human, despite the large interspecies difference in the metabolic clearance, which does not follow the usual allometric relationship.

Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

The physiologically based pharmacokinetics (PBPK) model, which combined methods Vd2 and CL2 yielded the most accurate predictions of in vivo terminal half-life (69% within 2-fold), demonstrates that PBPK models can lead to reasonable predictions of human pharmacokinetic predictions.

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

Overall improvement in prediction should facilitate the further application of WBPBPK modeling, where time, cost and labor requirements associated with experimentally determining Kpu's have, to a large extent, deterred its application.

Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat

  • S. PetersL. Hultin
  • Medicine, Chemistry
    Journal of Pharmacokinetics and Pharmacodynamics
  • 2007
PBPK simulations of a few compounds that are currently in drug discovery projects show that the observed initial absorption phase of their concentration-time profiles in rat were consistent with reduced gastric emptying rates, first time that the value of a generic PBPK model for hypothesis testing has been demonstrated with examples.

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

Improvement in parameter prediction was largely due to the incorporation of distribution processes related to drug ionisation, an issue that is not addressed in earlier equations.